Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Advanced Cell Diagnostics, Bio-Techne deal

    Advanced Cell Diagnostics Inc., Hayward, Calif. Bio-Techne Corp. (NASDAQ:TECH), Minneapolis, Minn. Business: Supply/Service Research supplier Bio-Techne will acquire Advanced Cell Diagnostics. Advanced Cell Diagnostics …

    Published on 7/11/2016
  • Amgen, Takeda deal

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Neurology, Cancer Takeda said it returned its Japanese rights to fulranumab (AMG 403) and trebananib (…

    Published on 7/11/2016
  • AstraZeneca, Leo Pharma deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Leo Pharma A/S, Ballerup, Denmark Business: Autoimmune, Dermatology AstraZeneca granted Leo exclusive, worldwide rights to tralokinumab (CAT-354) for dermatological …

    Published on 7/11/2016
  • AstraZeneca, Valeant Pharmaceuticals deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec Business: Autoimmune The companies terminated the European portion of a deal granting Valeant…

    Published on 7/11/2016
  • Carmot, Genentech, Roche deal

    Carmot Therapeutics Inc., San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Pharmaceuticals Carmot and Roches Genentech unit partnered to use …

    Published on 7/11/2016
  • Cormorant, Bristol-Myers deal

    Cormorant Pharmaceuticals AB, Stockholm, Sweden Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Bristol-Myers Squibb acquired Cormorant for $95 million in upfront and near-term milestone payments …

    Published on 7/11/2016
  • Effimune, J&J deal

    Effimune S.A.S., Nantes, France Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Autoimmune Johnson & Johnsons Janssen Biotech Inc. unit exercised an option to acquire exclusive, worldwide development and …

    Published on 7/11/2016
  • GlaxoSmithKline, NIH deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. National Institutes of Health, Bethesda, Md. Business: Infectious GlaxoSmithKline and NIHs Vaccine Research Center partnered to conduct laboratory studies of a Zika …

    Published on 7/11/2016
  • GlaxoSmithKline, Tsinghua University deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Tsinghua University, Beijing, China Business: Infectious The pharmas Beijing-based Institute for Infectious Diseases and Public Health and the universitys School of …

    Published on 7/11/2016
  • Infinity, AbbVie deal

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer Infinity said AbbVie ended the companies 2014 deal to co-develop and co-commercialize duvelisib (IPI-…

    Published on 7/11/2016
  • Medivation, Sanofi deal

    Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cancer Medivation said it entered into confidentiality agreements with a number of parties seeking to acquire …

    Published on 7/11/2016
  • Moderna Therapeutics, Merck deal

    Moderna Therapeutics Inc., Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Business: Cancer The companies partnered to develop and commercialize mRNA-based cancer vaccines that encode patient-specific …

    Published on 7/11/2016
  • Moderna Therapeutics, Vertex deal

    Moderna Therapeutics Inc., Cambridge, Mass. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Business: Pulmonary Moderna and Vertex partnered to discover and develop mRNA therapeutics to treat cystic fibrosis by…

    Published on 7/11/2016
  • Sanofi, Boehringer Ingelheim deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Generics, Veterinary Sanofi will exchange its Merial animal health unit for the consumer healthcare business of …

    Published on 7/11/2016
  • Sanofi, Walter Reed deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Walter Reed Army Institute of Research, Silver Spring, Md. Business: Infectious Sanofis Sanofi Pasteur vaccines unit and the institute partnered to co-develop a Zika vaccine…

    Published on 7/11/2016
  • TiGenix, Takeda deal

    TiGenix N.V. (Euronext:TIG), Leuven, Belgium Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Autoimmune TiGenix granted Takeda exclusive rights outside of the U.S. to develop and commercialize Cx601 …

    Published on 7/11/2016
  • UCB, Syndax deal

    UCB Group (Euronext:UCB), Brussels, Belgium Syndax Pharmaceuticals Inc. (NASDAQ:SNDX), Waltham, Mass. Business: Cancer UCB granted Syndax exclusive, worldwide rights to cancer candidate UCB6352 (now SNDX-6352), a mAb …

    Published on 7/11/2016
  • Uni-Bio Science Group, China Resources Pharmaceutical deal

    Uni-Bio Science Group Ltd. (HKSE:690), Hong Kong, China China Resources Pharmaceutical Group Ltd., Beijing, China Business: Ophthalmic Uni-Bio granted exclusive, Chinese commercialization rights to GeneSoft to the China…

    Published on 7/11/2016
  • Xencor, Novartis deal

    Xencor Inc. (NASDAQ:XNCR), Monrovia, Calif. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer Xencor granted Novartis rights to develop bispecific antibodies using Xencors technology, including rights…

    Published on 7/11/2016
  • Adaptive Biotechnologies, Argos deal

    Adaptive Biotechnologies Corp., Seattle, Wash. Argos Therapeutics Inc. (NASDAQ:ARGS), Durham, N.C. Business: Infectious, Cancer The companies partnered to study immune responses induced by Argos AGS-003 and AGS-004 …

    Published on 6/27/2016
  • Advanced Proteome Therapeutics, Wilex deal

    Advanced Proteome Therapeutics Corp. (TSX-V:APC;FSE:0E8), Boston, Mass. Wilex AG (Xetra:WL6), Munich, Germany Business: Cancer Advanced Proteome and Wilexs Heidelberg Pharma GmbH subsidiary partnered to create antibody-…

    Published on 6/27/2016
  • Cantabio, University of Antioquia deal

    Cantabio Pharmaceuticals Inc. (OTCQB:CTBO), Sunnyvale, Calif. University of Antioquia, Medellin, Colombia Business: Neurology Cantabio and the universitys Neuroscience Research Group will evaluate Cantabios small …

    Published on 6/27/2016
  • Celgene deal

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Celgene will provide $50 million to a newly formed consortium of four cancer centers as part of a 10-year deal to discover cancer treatments. Each institution …

    Published on 6/27/2016
  • Ciclofilin, ContraVir Pharmaceuticals deal

    Ciclofilin Pharmaceuticals Inc., San Diego, Calif. ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), New York, N.Y. Business: Infectious ContraVir acquired fellow HBV company Ciclofilin for up to $17 million in development …

    Published on 6/27/2016
  • Cipher, Edesa Biotech deal

    Cipher Pharmaceuticals Inc. (TSX:CPH;NASDAQ:CPHR), Mississauga, Ontario Edesa Biotech Inc., Markham, Ontario Business: Gastrointestinal Cipher granted Edesa rights to ASF-1096 to treat anorectal disorders. Cipher …

    Published on 6/27/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993